### promoting access to White Rose research papers



# Universities of Leeds, Sheffield and York http://eprints.whiterose.ac.uk/

This is the publisher's version of an article published in Nanoscale

White Rose Research Online URL for this paper:

http://eprints.whiterose.ac.uk/id/eprint/76241

### Published article:

Zhang, HY, Feng, GQ, Guo, Y and Zhou, DJ (2013) Robust, specific ratiometric biosensing using a copper-free clicked quantum dot-DNA aptamer sensor. Nanoscale, 5. ISSN 2040-3364

http://dx.doi.org/10.1039/C3NR02897F

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

**ARTICLE TYPE** 

## Robust, specific ratiometric biosensing using a copper-free clicked quantum dot-DNA aptamer sensor

Haiyan Zhang, a Guoqiang Feng, b Yuan Guo\*, a and Dejian Zhou\*, a

Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX 5 DOI: 10.1039/b000000x

We report herein the successful preparation of a compact, functional CdSe/ZnS core/shell quantum dot (QD)-DNA conjugate via the highly efficient copper-free "click chemistry" (CFCC) between a dihydrolipoic acid-polyethylene glycol-azide (DHLA-PEG-N<sub>3</sub>) capped QD and a cyclooctyne modified DNA. This represents an excellent balance between the requirements of high sensing sensitivity, robustness and 10 specificity for the QD-FRET (Förster resonance energy transfer) based sensor as confirmed by a detailed FRET analysis on the QD-DNA conjugate, yielding a relatively short donor-acceptor distance of ~5.8 nm. We show not only is this CFCC clicked QD-DNA conjugate able to retain the native fluorescence quantum yield (QY) of the parent DHLA-PEG-N<sub>3</sub> capped QD, but also is well-suited for robust, specific biosensing: it can directly quantitate pM level of both labelled and unlabelled complementary DNA 15 probes with good SNP (single-nucleotide polymorphism) discrimination ability in complex media, e.g. 10% human serum via target-binding induced FRET changes between the QD donor and dye accepter. Further, this sensor has also been successfully exploited for the detection of pM level of a specific protein target (thrombin) via the encoded anti-thrombin aptamer sequence in the QD-DNA conjugate.

### Introduction

20 The unique, size-dependent, highly stable and bright fluorescence of quantum dots (QDs) make them powerful tools in broad ranges of bio-related applications. <sup>1-4</sup> In particular, their broad absorption and narrow, symmetric emission are extremely well-suited for Förster resonance energy transfer (FRET) based sensing, because 25 these spectral characteristics enable a wide selection of excitation wavelengths to minimise direct excitation of the acceptor, reducing background and hence improving sensitivity. 1,2 Indeed, numerous QD-FRET based biosensors have been reported.<sup>3,4</sup> Despite these, the sensitivity and specificity of the OD-FRET 30 based biosensors have largely been limited by challenges in preparing compact, functional QD-bioconjugates that are stable and effectively resisting non-specific adsorption.<sup>2-4</sup> For example, water-soluble QDs prepared by ligand exchange are compact, but they often show low stability in biologically relevant buffers and 35 resistance to non-specific adsorption, limiting their sensing specificity and robustness.2 Whereas those prepared physical encapsulations with amphiphilic polymers and/or PEGylated lipids (where most commercial water-soluble QDs are based) are stable and can resist non-specific adsorption, but their large sizes 40 (with hydrodynamic radii often greater than the R<sub>0</sub> of most QDdye FRET pairs even prior to bioconjugation)<sup>2</sup> can greatly limit their FRET efficiency (sensitivity). Although FRET efficiency can be enhanced by increasing the ratio of acceptors on each OD, such designs are inefficient at low target to QD ratio situations.<sup>2</sup>


45 Therefore for biosensing, it is important balance the requirements of sensitivity and robustness because they are often incompatible. In this regard, QDs capped with PEGylated small-molecule ligands appeared to be highly attractive: they are relatively compact yet still displaying good stability and, more importantly, 50 effective resistance to non-specific adsorption of biomolecules.<sup>2</sup>

Besides surface capping, a robust, efficient QD-bioconjugation chemistry that can offer high bioactivity without compromising the QD fluorescence is also important. In this regard, the Cu(I) catalysed azide-acetylene cycloaddition, best known as the "click 55 chemistry" (CuCC), 5a is highly powerful and versatile: it offers exquisite function group selectivity and high yield. It has been used successfully in preparing a wide range of functional nanoparticle-bioconjugates (e.g. gold, magnetic, silica and polymer and) for sensing and biomedical applications.<sup>5</sup> However, the 60 CuCC is unsuitable for the QD, because the Cu(I) catalyst used in the CuCC can efficiently and irreversibly quench the QD fluorescence.<sup>6</sup> The Cu-free "click chemistry" (CFCC) between strained cyclooctynes and azide happens rapidly and efficiently, and moreover, it does not require any Cu catalyst. Therefore, the 65 CFCC appears to be idea for efficient QD-bioconjugation without compromising the QD fluorescence. 7a Indeed, the CFCC has been successfully used to make functional QD-protein/small-molecule conjugates recently for live virus labelling/imaging and intracellular trafficking studies.<sup>8</sup> Despite of such developments, the 70 QDs used in these studies were all capped with polymer based ligands (and hence of relatively big sizes) because the QD sizes

here are less critical for such applications. To our knowledge, the CFCC has yet to be used to develop QD-FRET based biosensors where a compact size of the QD-bioconjugate is known to be of critical importance. Herein, we report the successful preparation 5 of the first compact, functional QD-DNA conjugate via the CFCC between a dihydrolipoic acid-polyethylene glycol-azide (DHLA-PEG-N<sub>3</sub>) capped CdSe/ZnS core/shell QD and a cyclooctyne modified DNA, giving a good balance between the requirements of high sensitivity, specificity and robustness. This is supported by a FRET analysis showing a relatively short OD-dye distance of ~5.8 nm for the QD-DNA FRET system. Moreover, the CFCC clicked QD-DNA conjugate is found not only retaining the native fluorescence quantum yield (QY) of the parent QD, but also wellsuited for robust biosensing: it can directly quantitate pM level of 15 both labelled and unlabelled complementary DNA probes with good SNP (single-nucleotide polymorphism) discrimination ability even in complex media, e.g. 10% human serum, on a conventional fluorimeter. It can also directly detect pM level of a specific protein via the encoded DNA aptamer sequence.

#### 20 Results and discussion

### CFCC based QD-DNA conjugation and sensing principle



Scheme 1. (A) Schematic approach to the Cu-free "clicked" QD-DNA 25 conjugate. (B) Hybridization of a complementary dye-labelled DNA probe to the QD-DNA conjugate leads to QD sensitized dye FRET signal as readout for labelled DNA detection. (C) Incubation of the QD-doublestranded (ds)DNA conjugate formed in (B) with a longer, unlabeled DNA displaces the shorter labelled DNA reporter, reducing the QD to dye 30 FRET for label-free DNA detection. (D) Incubation of the QD-dsDNA conjugate (B) with a target protein that binds to the encoded aptamer sequence in the QD-dsDNA conjugate displaces the reporter DNA, leading to reduced QD to dye FRET for label-free protein detection. The block arrows give the FRET directions.

35 Scheme 1 shows our approach to the QD-DNA conjugate via the CFCC and its use in label- and label-free- detection of DNA and protein targets via target binding induced changes to the QD sensitized dye FRET signals. First, a multi-functional ligand, containing a dihydrolipoic acid (DHLA, for strong QD binding) 40 head group, a polyethylene glycol moiety of a molecular weight of 600 (PEG600, for providing a good water-solubility and effective resistance to non-specific adsorption of biomolecules) and a terminal azide group (for efficient DNA conjugation via the CFCC), DHLA-PEG600-N<sub>3</sub>, was prepared (see SI for details). <sup>9,10</sup> 45 A PEGylated DHLA ligand was used as the QD surface capping ligand here because it represented an excellent balance between the requirements of high stability and resistance to non-specific adsorption (for robust biosensing) and the structural compactness (for high sensitivity).<sup>2</sup> Then a hydrophobic CdSe/ZnS core/shell 50 QD (λ<sub>EM</sub> ~605 nm, QY ~20%, capped with hydrophobic trioctylphosphine oxide/trioctylphosphine) was made water-soluble by ligand exchange with the DHLA-PEG600-N<sub>3</sub> in a mixed solvent of CHCl<sub>3</sub>/ethanol using our previously established procedures,<sup>3</sup> yielding the QD-DHLA-PEG600-N<sub>3</sub> which was readily in polar 55 solvents. Its fluorescence QY was found to decrease to ~6.0% (and hence a decrease of ca 70%), which agreed well with most other literatures where most hydrophobic CdSe/ZnS core/shell QDs typically showed a QY decrease of 50-80% following the ligand exchange and transferred to aqueous media.<sup>3,4</sup> A single-60 stranded (ss) target DNA encoded with a 29 mer anti-thrombin (TB) aptamer sequence with strong affinity for TB ( $K_d \sim 0.5$  nM, modified with a C<sub>6</sub>-amine at 5', H<sub>2</sub>N-TBA, see Table 1)<sup>11</sup> was reacted with an N-hydroxysuccinimide (NHS) ester activated cyclooctyne to yield TBA-cyclooctyne, which was then reacted 65 with the QD-DHLA-PEG600-N<sub>3</sub> in a mixed solvent of ethanol/ water at a molar ratio of 30:1. This led to the QD-TBA covalent conjugation via the efficient CFCC approach. Approximately 20 strands of TBAs were found to have conjugated to each QD, denoted as QD-TBA20 hereafter, this gave a DNA conjugation 70 efficiency of ~67%. The detailed experimental procedures of the ligand synthesis and QD-DNA conjugation are given in the electronic supporting information (ESI). The QY of the resulting QD-TBA20 was determined as ~5.9% using Rhodamine 6G in

**Table 1.** The DNA sequences and their abbreviations used in this paper. TBA is modified with C<sub>6</sub>NH<sub>2</sub> at 5', and all other DNAs are labelled with an Atto-647N at 3'. The sequences of DNA29, DNA18, DNA15 and 80 DNA12 are fully complementary to TBA, but DNA12-SM contains a single-base mismatch (shown in bold italic). The 29 mer anti-thrombin aptamer sequence encoded in TBA is shown in italic. DNA29-NL has the sequence as DNA29 but without the Atto647N label.

ethanol as the calibration standard (QY 95%), 3b which is 75 effectively the same as the QD-DHLA-PEG600-N<sub>3</sub> (ca. 6.0%).

	DNA code Sequence				
85	TBA	5'-TTAGTCCGTGGTAGGGCAGGTTGGGGTGACT-3'			
	DNA29	3'-TCAGGCACCATCCCGTCCAACCCCACTGA-5'			
	DNA18	3'-AATCAGGCACCATCCCGT-5'			
	DNA15	3'-AATCAGGCACCATCC-5'			
	DNA12	3'-TCAGGCACCATC-5'			
90	DNA12-SM	3'-TCAGACACCATC-5'			
	DNA-NC	3'-TAGTCC CGATT TCTCACG-5'			

The QD-TBA20 was found to be highly soluble and stable in aqueous media. It showed no change of physical appearance or 95 fluorescence after being stored in a fridge at 4 °C for over two months. More importantly, the QD-TBA20 was found to have effectively retained the native QY of the parent QD-DHLA-PEG600-N<sub>3</sub>. In contrast, conjugation of the H<sub>2</sub>N-TBA to a water-

soluble, glutathione capped QD (the same batch of QD, QY = ~18% in water) by using 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide (EDC)/NHS mediated covalent coupling resulted in significantly reduced QY. The fluorescence intensity of former 5 was ~6.4 times as strong as the later (see ESI, Fig. S1). Moreover, the number of TBA strands conjugated to each QD by the CFCC (20) was also 4 times that of the later (~5). All these demonstrate that the CFCC based OD-DNA conjugation approach developed herein is far superior over the EDC/NHS mediated coupling, a 10 conventional widely used OD-bioconjugation method,<sup>3</sup> in terms of both DNA conjugation efficiency and ability of maintaining a high QY of the QD.

### FRET analysis of the CFCC clicked QD-DNA conjugate.

Prior to using the CFCC clicked OD-DNA conjugate for sensing, a FRET analysis on the CFCC clicked QD-DNA conjugate hybridised with a complementary strand (DNA29) was carried out to ensure a relatively small donor-acceptor distance (r) for high sensitivity. This is because FRET efficiency (E) decreases dramatically with the increasing r value following the Förster 20 dipole-dipole interaction formula:

$$E = 1/[1 + (r/R_0)^6] \tag{1}$$

Where  $R_0$  is the Förster radius of the single donor (QD)-single acceptor (Atto647N) FRET pair here, under which E = 50%.  $R_0$ can be estimated from the spectral overlap (I) and the QY of the 25 QD donor *via* the following equation:

$$R_0 = \left(\frac{[9000 \cdot (\ln 10)]k_p^2}{128 \pi^5 n_D^4 N_A} QY \times I\right)^{1/6} \tag{2}$$

Where  $n_D$  is the refractive index of the medium (estimated as 1.4 here);  $N_A$  is Avogadro's number (6.02×10<sup>23</sup>);  $k_p^2$  is the orientation factor (2/3 here assuming randomly orientated fluorophores). The 30 integral of the spectral overlap, *I*, is defined as:

$$I = \int_0^\infty J(\lambda) = \int_0^\infty F_D(\lambda) \, \epsilon_A(\lambda) \, \lambda^4 \, d\lambda \tag{3}$$

I is the integral of the donor-acceptor spectral overlap over all wavelengths  $\lambda$ ;  $F_{D-corr}$  is the normalized donor emission and  $\varepsilon_A$  is the absorption extinction coefficient of the acceptor.

The normalised absorption and emission spectra of the QD and Atto647N are shown in ESI, Fig. S1A. A significant overlap between the QD (donor) emission and Atto647N (acceptor) absorption is clear, suggesting the two can have efficient FRET. The donor-acceptor spectra overlap, *I*, can be calculated from Fig.  $_{40}$  S1B, giving a value of  $6.68 \times 10^{15}$  M<sup>-1</sup>.cm<sup>-1</sup>.nm<sup>4</sup>. These combined with the QY of the QD (5.9%) and the parameters above, yield a  $R_0$  value of 4.25 nm for the QD-Atto647N FRET pair (at 1:1

For a single-donor (QD here) simultaneously FRET with n 45 identical acceptors system, E is given by the following equation:

$$E = nR_0^6 / [r^6 + nR_0^6]$$
 (4)


Where the apparent E can be estimated directly from the acceptor fluorescence enhancement *via* the following equation:

Apparent 
$$E = I_A/[I_A + I_D]$$
 (5)

Where  $I_A$  and  $I_D$  are the integrated acceptor and donor

fluorescence intensities, respectively. Here a ratiometric FRET analysis is used which can be more reliable than those only based on donor quenching because it can be essentially insensitive to instrument noise and signal fluctuations, making analysed result potentially more accurate. Moreover,  $I_A$  here only comes from the QD-sensitised FRET because the acceptor is not directly excited under our experimental conditions (see next section below) and any unbound species will be too far away to participate the FRET process, and hence not interfering with target detection, allowing 60 highly convenient, separation-free measurement.

The FRET study was carried out with 2 nM of the QD-TBA<sub>20</sub> (2 nM) sample after hybridization with different molar equivalent of DNA29 (3'-labelled with an Atto647N acceptor, see Table 1). Hybridization of DNA29 to the QD-TBA<sub>20</sub> should bring the 65 Atto647N acceptor to the close proximity to the QD, leading to QD sensitized Atto-647N FRET signal upon excitation of the QD (Scheme 1B). For Equation (4) to be valid, all DNA29 strands introduced (and Atto647N labels) should bind to the QD-TBA<sub>20</sub> Hence the longest DNA29 probe which forms the most stable 70 duplex with the QD-TBA<sub>20</sub> was used.






Fig. 1. (A) Fluorescence spectra of QD-TBA<sub>20</sub> (2 nM) hybridised with different molar equivalent of DNA29 with 7µM His6-Cys peptide. The 75 DNA29 only curve has a concentration of 60 nM. (B) A plot of the apparent E as a function of DNA29/QD molar ratio, data were fitted using equation (4), yielding a r value of 5.82±0.01 nm.

Fig. 1A clearly shows that with the increasing molar ratio of 80 the DNA29:QD-TBA20, the QD fluorescence is quenched while the Atto647N FRET signal is increased progressively, suggesting efficient FRET between the QD and Atto647N dye. Moreover, the resulting E and DNA29/QD molar ratio can be fitted well by the single-QD donor FRET with multiple identical acceptor model ( $R^2 = 0.99$ ) with a relatively short donor-acceptor distance r of 5.82±0.01 nm. This result confirms that the CFCC clicked QD-DNA conjugate FRET system is indeed compact, and r moreover, all Atto647N labels on the DNA29 strands are bound to the QD at an identical spatial separation (the same QD-dye distance r).

### Detection of DNA29 using the CFCC clicked QD-TBA20.

The sensitivity of the QD-TBA<sub>20</sub> based FRET sensor in detecting complementary DNA probes was further evaluated by using DNA29. Hybridization of DNA29 to the QD-TBA<sub>20</sub> should bring the Atto647N dye (acting as the FRET acceptor) to the close proximity to the QD, leading to QD sensitized Atto647N FRET signal upon excitation of the QD. A significant advantage of FRET based signal readout over other approaches (*e.g.* donor quenching or life time change) is its ratiometric signal, which can be effectively insensitive to signal fluctuation and instrument noise, allowing for more reliable, accurate detection. Moreover, since FRET only happens over short distances (*ca.* < 10 nm), any free, unbound species will be too far to FRET with the QD donor and hence undetected, allowing for convenient probe detection to be carried out in a separation-free format. Interestingly, the 25 QD-TBA<sub>20</sub> (C<sub>OD</sub> = 2 nM) fluorescence in PBS (10 mM sodium

phosphate, 150 mM NaCl, pH 7.40) was found to be enhanced significantly after treatments with a cysteine-histidine, short peptide and/or bovine serum albumin (BSA, see ESI, Fig. S2A). Presumably because these molecules can bind or adsorb onto the 30 QD-TBA20 to enhance the QD fluorescence QY as reported previously.3a They may also adsorb onto sample tubes to reduce the non-specific adsorption and/or salt-induced aggregation of the OD. Moreover, the added peptide/BSA was also found to improve the FRET efficiency of the QD-TBA/DNA29 system 35 considerably (see ESI, Fig. S2B), and the effect became saturated at ~7 µM. With the peptide/BSA being added, the hybridized QD-TBA<sub>20</sub>/DNA29 FRET system was found to be highly stable, no significant change of the QD fluorescence or Atto647N FRET signals were observed after being stored for 18 hrs in PBS (see 40 ESI, Fig. S3). This is important for biosensing, allowing the experiments to be carried out at ease without the need to worry about the stability of the sensor (from our own experience, most small-molecule ligands capped QDs, including glutathione, 3mercaptopropinoic acid (MPA) and DHLA, showed rather 45 limited stability in PBS, and therefore all sensing measurements should be performed within 1 h after target addition to avoid significant decrease of the QD fluorescence). 31,3m,3n,4d,4e All subsequent sensing experiments were carried out with 7 µM added peptide/BSA on a conventional fluorimeter with a low QD 50 concentration of 2 nM.




Fig. 2. (A) Fluorescence spectra of the QD-TBA $_{20}$  ( $C_{QD} = 2$  nM) after hybridization with different amounts of DNA29 for 2 hrs in PBS excited at 450 nm, the  $\lambda_{abs}$  minimum of Atto647N. (B) A plot of the integrated donor/accepter fluorescence ratio,  $I_{Dye}/I_{QD}$ , as a function of [DNA29]. The data were fitted to a two-stage linear relationship with fitting parameters of y = -0.539 + 0.1121x,  $R^2 = 0.9978$  over 10-40 nM, and y = -0.000395 + 0.0354x,  $R^2 = 0.9947$  over 55 0-5 nM (shown in the inset), which the detection limit based on. (C) Plot of the  $I_{Dye}/I_{QD}$  ratios as a function of concentration for different length complementary DNA probes. (D) The  $I_{Dye}/I_{QD}$  ratios for different length DNA probes at 40 nM.

### Journal Name

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

### ARTICLE TYPE

Fig. 2A shows that in general the QD fluorescence (peaking at ~605 nm) was quenched progressively together with a concurrent simultaneous significant increase of the Atto647N FRET signal (peaking at ~665 nm) with the increasing DNA29 concentration, <sup>5</sup> [DNA29], suggesting efficient QD-sensitised dye FRET from hybridisation of the DNA29 to QD-TBA20. A careful examination of the Atto647N emission spectra over 640-700 nm range revealed that the Atto647N emission obtained from direct excitation of 60 nM DNA29 was actually weaker than that of the 10 QD-sensitized FRET signal for 0.25 nM DNA29 (see ESI, Fig. S4), suggesting the QD sensitized FRET is at least 240 times as efficient as direct excitation. To our knowledge, this is the highest ratio of FRET-sensitized signal over that of direct excitation for the QD-FRET systems reported so far (most literature ratios are 15 typically ranged from ~2.5-40). This is presumably because  $\lambda_{EX}$ = 450 nm, corresponding to the  $\lambda_{abs}$  minimum of the Atto647N, was used here to minimise the direct excitation of the Atto647N acceptor. Moreover, the CFCC conjugated QD-TBA20 here retained a much higher QY of the QD than those prepared via the 20 EDC/NHS coupling (see ESI, Fig. S1), as a result, the sensing experiments were able to be performed at 2 nM QD, ~10-100 fold lower than those reported previously.<sup>2,3</sup> Such a high FRETsensitised signal over direct excitation background is highly advantageous for biosensing, which can effectively eliminate the 25 need of background correction from direct acceptor excitation, making data analysis easy and straightforward.

Despite the QD fluorescence did not always follow a simple trend of progressive quenching with the increasing [DNA29], especially at low [DNA29] shown in Fig. 2A, possibly due to a 30 slight increase of the QD QY as DNA29 was hybridized, this had

no impact on the ratiometric based data analysis employed here. In fact, the ratio of integrated fluorescence intensity between the acceptor and donor, I<sub>Dve</sub>/I<sub>OD</sub> (see ESI for detailed calculation method)<sup>31</sup> displayed a two-stage linear dependence with the 35 increasing [DNA29]: a slow increasing phase over low [DNA29]  $(0-5 \text{ nM}, \text{ slope: } 0.0353 \text{ nM}^{-1}, \text{ R}^2 = 0.9947)$  and a more rapid phase at higher concentrations (10-40 nM, slope: 0.1121 nM<sup>-1</sup>, R<sup>2</sup>=0.9978, Fig. 2B). As [DNA29] was increased to above 40 nM, the I<sub>Dye</sub>/I<sub>QD</sub> value showed little further increase, suggesting 40 the hybridization reached saturation. Thereafter, any extra added DNA29 strands were unable to hybridize to the QD-TBA20 and would remain free. Since FRET only takes place over short distances (ca. < 10 nm), such free DNA29 strands are unable to participate the FRET process and hence undetected. Note here 45 that 40 nM corresponds to the total [TBA] in the 2 nM QD-TBA<sub>20</sub> conjugate, suggesting that all TBAs conjugated to the QD are functional and available for hybridization. The detection limit (DL) for DNA29, based on 3 times the standard deviations/slope of linear calibration over the lower concentration range 50 (3σ/slope) is estimated as ~91 pM, <sup>3h</sup> making it one of the most sensitive QD-FRET based sensors for direct DNA quantification without probe pre-amplification using conventional fluorescence spectroscopy (see Table 2). Moreover, this level of sensitivity is also comparable or better than many other sensitive direct DNA 55 detection methods without probe pre-amplification, such as the optimised, sensitive microcantilever sensor (~10 pM), <sup>12b</sup> electrochemical detection (10 pM), <sup>12c</sup> surface plasmon resonance (SPR, 10 nM)<sup>12d</sup> and quartz crystal microbalance (QCM, 10 nM)<sup>12e</sup> detection (see Table 2 for details).

Table 2. Comparison of the sensitivity and specificity of some QD-FRET and other direct DNA detection techniques without probe amplification.

Detection System	Target/length	Specificity	SNP DR	LOD (nM)	Ref
QD-BRET	DNA/22 mer	?	?	20	[30]
QD-FRET	DNA/19 mer	< 2	no	40 (1 μM QD)	[3g]
65 QD-FRET	DNA/24 mer	< 2	no	12 (0.06 μM QD)	[3g]
QD-FRET	DNA/25 mer	~3	no	200	[3p]
QD-FRET	DNA/18-32 mer	2-3	no	~5	[3q]
QD-FRET	DNA/30 mer	34	no	0.5	[3m]
QD-FRET	DNA/15 mer	?	no	0.4	[3r]
70 QD-FRET	DNA/12-29 mer	816	3.3 (12 mer)	0.091 (29 mer)	This work
Microcantilever	DNA/12 mer	?	?	75	[12a]
Microcantilever	DNA/12 mer	~3	?	~0.010	[12b]
Electrochemical	DNA/24 mer	?	?	0.01	[12c]
Electrochemical	DNA/34 mer	yes	1.5-2.0	0.05	[12d]
75 Direct SPR	DNA/16mer	?	?	10	[12e]
Direct QCM	DNA/509 mer	?	?	10	[12f]

BRET: bioluminescence resonance energy transfer; LOD: Limit of detection; Specificity: FRET ratio between the full- and non-complementary DNA probes; SNP DR: SNP discrimination ratio.

Theoretically, a linear correlation between the I<sub>Dve</sub>/I<sub>OD</sub> and probe concentration, [DNA29], is expected if all introduced DNA probes are hybridized to the QD-TBA20 at identical position (the same QD-dye distance, r). 13 The excellent linear relationship observed here clearly confirmed that all DNA29 strands were 85 hybridized to the QD at identical spatial separations between the QD donor and dye acceptor. This result also agrees well with the earlier FRET analysis where E can be fitted very well ( $R^2$  = 0.991) by the single-donor with multiple identical acceptors FRET interaction model.<sup>2</sup> The two-stage linear dependences observed here may indicate two different phases of DNA hybridization: the slower increase over 0-5 nM range is likely due to incomplete hybridization of DNA29 to the QD-TBA<sub>20</sub>, arising presumably from the low, sub- $K_d$  levels of [DNA29]; whereas the s faster increase over 10-40 nM range may be attributed to more effective, complete binding of the introduced DNA29 to the QD-TBA<sub>20</sub> under such conditions. Given that  $K_d$  values of 17, 19 and 41 nM have been reported for a 25, <sup>14a</sup> 20, <sup>14b</sup> and 12 <sup>12a</sup> mer dsDNAs, respectively, we believe such explanations here are highly plausible.

The CFCC clicked QD-DNA FRET sensor was found to be highly specific: incubation of the QD-TBA20 with a noncomplementary probe (DNA-NC, also 3'-Atto647N labelled, see Table 1) under identical conditions (with 10 µM added BSA)  $_{15}$  produced effectively non-detectable FRET. The  $I_{Dye}/I_{QD}$  ratios for the DNA29 and DNA-NC (both at 30 nM) were determined as 2.563 and 0.00314, respectively, yielding an outstanding signal discrimination ratio of 816 between the full- and non- complementary DNA probes (see ESI, Fig. S6). The discrimination ratio 20 here is 24-400 folds higher than previously reported QD-FRET based DNA sensors (see Table 2), demonstrating an excellent DNA sensing specificity. Moreover, the OD-FRET based DNA sensor was highly robust, it worked pretty well even in clinically relevant media, e.g. 10% human serum (see ESI, Fig. S7). It 25 should be noted that despite numerous QD-FRET based DNA sensors have been reported in literature, few have demonstrated working function in serum, one of the most frequently used clinical media. These results clearly demonstrated an excellent sensing specificity and robustness of the CFCC clicked OD-DNA 30 sensor, which we attribute to the excellent stability, and more importantly, the outstanding resistance toward non-specific adsorption of biomolecules afforded by the PEGylated capping ligands on the QD surface. 9,10


### Detection of different length DNA probes and SNP (single-35 nucleotide polymorphism) discrimination

Besides offering high discrimination between complementary and non-complementary DNA probes, the CFCC clicked QD-DNA sensor can effectively discriminate complementary DNA probes of different lengths. As shown in Fig. 2C, although the I<sub>Dve</sub>/I<sub>OD</sub> 40 ratios increased with the increasing concentration for all probes, the rates of increase were significantly different, with DNA29 being the fastest while DNA12-SM being the slowest. A general trend here is that the I<sub>Dve</sub>/I<sub>OD</sub> increase rate showed a positive correlation to the length of the DNA probe, e.g. DNA29 > 45 DNA18 > DNA15 > DNA12 > DNA12-SM. Moreover, DNA18 also showed a two-stage  $I_{Dve}/I_{OD}$ –[DNA] linear increase similar to that for DNA29, while for DNA15 and DNA12, this became much less clear, and DNA12-SM effectively displayed a single linear dependence. Such differences may reflect their different  $_{50}$   $K_{d}$ s of the different length probes toward the common TBA target: only those with  $K_d$ s that span across the [DNA] range studied here may display two-stage dependences.

The slopes of the rapid increasing  $I_{Dye}/I_{QD}$  phase (over 10-40 nM range) were found to be 0.112, 0.091, 0.062, 0.036 and 0.011 ss nM<sup>-1</sup> for DNA29, DNA18, DNA15, DNA12 and DNA12-SM, respectively. Therefore the slope of  $I_{Dye}/I_{QD}$  increase rate for the DNA29 is ~ 3 times that of DNA12; while that for DNA12 is a

further ~3.3 times that of DNA12-SM, the same length (12 mer) probe containing just a single base mismatch to TBA, equivalent 60 to a single nucleotide polymorphism (SNP). The CFCC clicked QD-DNA sensor can therefore offer a SNP discrimination ratio of ~3.3 for the 12 mer DNA probes. Similar levels of probe length dependences and SNP discrimination ratio (ca. > 3 between DNA12 and DNA12-SM) were also obtained from the I<sub>Dve</sub>/I<sub>OD</sub> 65 ratios at 40 nM probe concentration (Fig. 2D). More interestingly, the discrimination between DNA12 and DNA12-SM was found to be unaffected by the presence of complex media, such as 10% human serum. In fact, the discrimination ratio actually increased to 6.1 (against ~3 in PBS, see ESI, Fig. S8), demonstrating a good 70 potential for SNP based clinical diagnosis. It should be noted that despite several QD-FRET based DNA sensors have been reported in literature, most of which displayed rather low discrimination ratios between full- and non- complementary DNA probes, few have displayed SNP discrimination ability (see Table 2). Since 75 SNPs are known to be closely associated with a number of important human diseases, such as cancer, neurodegenerative diseases and diabetes etc,15 the excellent specificity, sensitivity and robust SNP discrimination ability in complex media may make the CFCC clicked QD-DNA sensor potentially suitable for 80 clinical applications.

#### **Detection of unlabelled DNA probe**



**Fig. 3.** (**A**) Typical fluorescence spectra of QD-TBA<sub>20</sub> (2 nM) prehybridized to DNA12-SM (60 nM) after addition of different [DNA29-NF] for 2 hrs. (**B**) A plot of the corresponding fluorescence intensity ratio at 605 and 665 nm (I<sub>605</sub>/I<sub>665</sub>) as a function of [DNA29-NF], inset shows response curve at the sub-nM range.

The ability of detecting unlabeled DNA probes is more useful for potential clinical applications, avoiding the need of the probe

labelling step which can be complex, expensive and sometimes even impossible. In this regard, a new DNA displacement assay is developed here: a longer unlabeled probe (e.g. DNA29-NL, with the same sequence as DNA29 but without the Atto647N label) 5 that forms more stable duplex with TBA can effectively displace a shorter labelled DNA (e.g. DNA12-SM, acting as a FRET reporter) pre-hybridized to the QD-TBA20, leading to a decreased FRET as the unlabelled probe readout signal (Scheme 1C).

Fig. 3 reveals that this is indeed feasible: where the Atto647N 10 FRET signal at ~665 nm was almost diminished accompanied with a concurrent significant recovery of the QD fluorescence at 605 nm as the [DNA29-NL] was increased, suggesting a successful displacement of the DNA12-SM reporter strand by the DNA29-NL, leading to a significant increase (~21 fold) of the <sub>15</sub>  $I_{605}/I_{665}$  ratio (from 1.32± 0.06 to 28.6 ± 2.2 as the [DNA29-NL] increased from 0 at 100 nM, see Fig. 3B). Interestingly, replacing the DNA12-SM with DNA12 as the FRET reporter strand led to a much smaller increase of the  $I_{605}/I_{665}$  ratio under identical conditions (from 0.66  $\pm$  0.02 to 3.48  $\pm$  0.09, an increase of ~5.3 20 fold, see ESI, Fig. S9 for details), suggesting that a high stability difference between the reporter and probe DNAs for the common target is key to achieve efficient reporter strand displacement and hence greatly increased  $I_{605}/I_{665}$  ratio. The  $I_{605}/I_{665}$  response curve as a function of [DNA29-NL] was found to be non-linear (Fig. 25 3B), where 500 pM [DNA29-NL] produced a signal consistently above the background (Fig. 3B inset), suggesting this sensor can readily detect 500 pM DNA29-NL without probe amplification. Therefore this signal-on DNA sensing approach developed here can readily detect ~500 pM unlabelled DNA probes together with <sub>30</sub> a maximum ratiometric signal enhancement of ~ 21 fold, which is already competitive against some other more established DNA sensing approaches, such as molecular beacons (ca. 10-20 fold signal enhancement with single-quenchers sensitivity)11b,11c and a recently optimised electrochemical DNA sensor (ca. 8 fold). 12d An advantage of our approach here is its ratiometric signal, which can be effectively insensitive to instrument noise and signal fluctuation, allowing more reliable target detection. In addition, the DNA displacement assay was found to work equally efficient in complex media, such as PBS 40 with large excess of BSA (10 μM) and in 10% human serum, suggesting it may have good potential for clinical application.

### **Detection of unlabelled protein**

The CFCC clicked QD-TBA<sub>20</sub> can be readily extended for label-free protein sensing via the anti-thrombin DNA aptamer 45 sequence encoded within the TBA sequence: where the formation of thrombin (TB)/TBA complex can effectively displace the prehybridised reporter DNA12-SM, leading to FRET decrease (and hence an increase of the I<sub>605</sub>/I<sub>665</sub> ratio, see Scheme 1D). Figure S10 (ESI) revealed this was indeed true, where the Atto647N 50 FRET signal gradually was decreased while the QD fluorescence was increased concurrently as the target [TB] was increased, leading to increased I<sub>605</sub>/I<sub>665</sub> ratio (see Fig. 4). The maximum I<sub>605</sub>/I<sub>665</sub> ratio obtained at 100 nM TB here (~3.1) was not as high as that obtained in DNA29-NF detection (~29), suggesting that 55 the TB binding here is less efficient in displacing the DNA12-SM reporter strands from the QD-TBA20 conjugate as compared to DNA29-NF. Given that the binding affinity between the 29 mer

anti-TB aptamer and TB  $(K_d \sim 0.5 \text{ nM})^{11a}$  is as strong as that of the TBA/DNA29 duplex (~0.3 nM estimated above) here, the 60 relatively low efficiency in displacing the reporter strands observed for TB here is therefore attributed to the significantly greater size of the TB-aptamer complex as compared to TBA/DNA29 duplex, leading to steric hindrance and reduced accessibility for TB binding on the QD-DNA conjugate, 65 especially under high [TB] situations. Similar to the DNA29-NL based displacement assay above, a non-linear response curve between the  $I_{605}/I_{665}$  signal and [TB] was also observed (Fig. 4). Moreover, the amplified response curve over 0-2 nM [TB] range revealed that 500 pM [TB] produced a signal consistently above 70 the background (Fig. 4, inset), suggesting the CFCC clicked QD-DNA aptamer sensor can detect 500 pM TB directly without target pre-amplification. This sensitivity achieved here is among the most sensitive QD-FRET based label-free TB sensors using direct target detection without pre-amplification (see ESI, Table 75 S1). Moreover, this sensitivity is also comparable to other more established electrochemical sensing method for TB detection (with a detection limit of  $\sim 1 \text{ nM}$ ). <sup>12g</sup>




Fig. 4. Label-free detection of thrombin using the CFCC clicked QD-DNA aptamer sensor using 2 nM QD-TBA20 pre-hybridized to DNA12-80 SM (60 nM) in PBS containing 20 μM BSA. A typical calibration curve showing the I<sub>605</sub>/I<sub>665</sub> ratio as a function of thrombin concentration [TB] (inset: the response over 0-2 nM of [TB]).

### Conclusion

85 In summary, we have successfully developed a reliable CFCC approach for the preparation of a compact, stable QD-DNA/ aptamer conjugate that can retain the native fluorescence QY of the parent QD. The resulting QD-DNA conjugate has been used for robust, sensitive and ratiometric quantitation of specific DNA 90 probes directly with pM sensitivity even in complex media, such as 10% human serum. This QD-DNA FRET sensor has offered an excellent signal discrimination (> 800 fold) between the fulland non-complementary DNA probes, which is the highest for the OD-FRET based sensors. Moreover, it can discriminate between 95 the perfect-match and SNP targets in 10% serum. The sensor has also been exploited for sensitive label-free detection of pM level of thrombin via the anti-thrombin aptamer sequence encoded in the QD-DNA conjugate. This QD-DNA/aptamer sensor can be readily extended for detection of other DNA and protein targets 100 by clicking other specific DNA/aptamer sequences against such targets.16 Given its high stability, specificity, robustness and sensitivity, the CFCC clicked QD-DNA/aptamer sensor sensitivity, the CFCC clicked QD-DNA/aptamer sensor appears to have good potential in a wide range of biosensing and diagnostic applications.

### 5 Acknowledgments

We thank the University of Leeds, the Leeds Biomedical Health

### **Notes and references**

- School of Chemistry and Astbury Centre for Structural Molecular
  Biology, University of Leeds, Leeds LS2 9JT (United Kingdom).
  E-mail: y.guo@leeds.ac.uk (YG)
  d.zhou@leeds.ac.uk (DZ)
  - b College of Chemistry, Central China Normal University, 152 Luoyu Road, Wuhan 430079, P.R. China.
- 20 † Electronic Supplementary Information (ESI) available: details on the synthesis, purification and characterisation of the DHLA-PEG600-N<sub>3</sub>, cyclooctyne-DNA, and the QD-TBA<sub>20</sub> conjugate as well as all supporting figures and tables. See DOI: 10.1039/b000000x/
- a) P. Alivisatos, *Nat. Biotechnol.* 2004, 22, 47; b) X. Michalet, F. F. Pinaud, L. A. Bentolila, J. M. Tsay, S. Doose, J. J. Li, G. Sundaresan, A. M. Wu, S. S. Gambhir and S. Weiss, *Science* 2005, 307, 538; c) I. L. Medintz, H. T. Uyeda, E. R. Goldman and H. Mattoussi, *Nat. Mater.* 2005, 4, 435; d) R. C. Somers, M.G. Bawendi and D.G. Nocera, *Chem. Soc. Rev.* 2007, 36, 579.
- a) I. L. Medintz and H. Mattoussi, Phys. Chem. Chem. Phys. 2009,
  11, 17; b) W. R. Algar, D. E. Prasuhn, M. H. Stewart, T. L. Jennings,
  J. B. Blanco-Canosa, P. E. Dawson and I. L. Medintz, Bioconjugate Chem. 2011, 22, 825; c) H. Mattoussi, G. Palui and H. B. Na, Adv.
  Drug Del. Rev. 2012, 64, 138; d) D. J. Zhou, Biochem. Soc. Trans.
  2012, 40, 635; e) Z. Jin and N. Hildebrandt, Trends Biotech. 2012,
  30, 394.
- a) T. Pons, I. L. Medintz, X. Wang, D. S. English and H. Mattoussi, J. Am. Chem. Soc. 2006, 128, 15324; b) D.J. Zhou, J. P. Piper, C.
  Abell, D. Klenerman, D.-J. Kang and L. M. Ying, Chem. Commun. 2005, 4807; c) M. Suzuki, Y. Husimi, H. Komatsu, K. Suzuki and K. T. Douglas, J. Am. Chem. Soc. 2008, 130, 5720; d) Q. Wang, Y. Liu, Y. Ke and Yan, H. Angew. Chem. Int. Ed. 2008, 47, 316; e) H. Peng, L. Zhang, T. H. M. Kjallman, C. Soeller and J. Travas-Sejdic, J. Am. Chem. Soc. 2007, 129, 3048; f) D. E. Prasuhn, J. B. Blanco-Canosa,
- G. J. Vora, J. B. Delehanty, K. Susumu, B. C. Mei, P. E. Dawson and I. L. Medintz, *ACS Nano* 2010, **4**, 267; g) W. R. Algar and U. J. Krull, *Anal. Chim. Acta* 2007, **581**, 193. h) J. Liu, J. H. Lee and Y. Lu, *Anal. Chem.* 2007, **79**, 4120; i) H. Yao, Y. Zhang, F. Xiao, Z. Xia and J. Rao, *Angew. Chem. Int. Ed.* 2007, **46**, 4346; j) I. L. Madintz, L. Berti, T. Pons, A. F. Grimes, D. S. English, A. Alessandrini, P. Facci and H. Mattoussi, *Nano Lett.* 2007, **7**, 1741; k) R. Freeman, T.
- Finder and I. Willner, *Angew. Chem. Int. Ed.* 2009, **48**, 7818; I) D. J. Zhou, L. M. Ying, X. Hong, E. A. Hall, C. Abell and D. Klenerman, *Langmuir* 2008, **24**, 1659; m) D. J. Zhou, Y. Li, E. A. H. Hall, C. Abell and D. Klenerman, *Nanoscale* 2011, **3**, 201; n) H. Y. Zhang, P. G. Stockley and D. J. Zhou, *Faraday Discuss*. 2011, **149**, 319; o) K. A. Cissell, S. Campbell, S. K. Deo, *Anal. Bioanal. Chem.* 2008, **391**, 2577; p) J. Lee, Y. Choi, J. Kim, E. Park, R. Song, *ChemPhysChem*,
- 2009, 10, 806; q) H. Peng, L. Zhang, T. H. M. Kjallman, C. Soeller,
  J. Travas-Sejdic, J. Am. Chem. Soc., 2007, 129, 3048; r) G.-I. Kim,
  K.-W. Kim, M.-K. Oh, Y.-M. Sung, Nanotechnology 2009, 20, 175503
- a) M. Levy, S. F. Cater and A. D. Ellington, ChemBioChem. 2005, 6, 2163. b) C. Y. Zhang, H. C. Yeh, M. T. Kuroki and T. H. Wang, Nat. Mater. 2005, 4, 826; c) E. Oh, M. Y. Hong, D. Lee, S. H. Nam, H. C. Yoon and H. S. Kim, J. Am. Chem. Soc. 2005, 127, 3270; d) Y. Zhang, H. Y. Zhang, J. Hollins, M. E. Webb and D. J. Zhou, Phys. Chem. Chem. Phys. 2011, 13, 19427; e) H. Y. Zhang and D. J. Zhou, Chem. Commun. 2012, 48, 5097; f) H. Lu, O. Schöps, U. Woggon and C. M. Niemeyer, J. Am. Chem. Soc. 2008, 130, 4815; f) D.

- Research Centre and the Leeds Cancer Research UK Centre for supporting this work. HZ thanks the EPSRC (UK) for providing a DTA research studentship to support her study at University of Leeds. YG thanks the Wellcome Trust for providing a Career Reentry Fellowship.
  - Geiβler, L. J. Charbonnière, R. F. Ziessel, N. G. Butlin, H.-G. Löhmannsröben and N. Hildebrandt, *Angew. Chem.Int. Ed.* 2010, **49**, 1396.
- a) V. V. Rostovtsev, L. G. Green, V. V. Fokin and K. B. Sharpless, Angew. Chem. Int. Ed. 2002, 41, 2596; b) E. Lallana, E. Fernandez-Megia and R. Riguera, J. Am. Chem. Soc. 2009, 131, 5748; c) N. Li and W. H. Binder, J. Mater. Chem. 2011, 21, 16717; d) E. Boisselier, L. Salmon, J. Ruiz and D. Astruc, Chem. Commun. 2008,5788; e) L. Nebhani and C. Barner-Kowollik, Adv. Mater. 2009, 21, 3442; f) G. von Maltzahn, Y. Ren, J.-H. Park, D.-H. Min, V. R. Kotamraju, J. Jayakumar, V. Fogal, M. J. Sailor, E. Ruoslahti and S. N. Bhatia, Bioconjugate Chem. 2008, 19, 1570.
- 6 a) A. Bernardin, A. Cazet, L. Guyon, P. Delannoy, F. Vinet, D. Bonnaffé and I. Texier, *Bioconjugate Chem.* 2010, 21, 583; b) G. Beaune, S. Tamang, A. Bernardin, P. Bayle-Guillemaud, D. Fenel, G. Schoehn, F. Vinet, P. Reiss and I. Texier, *ChemPhysChem* 2011, 12, 2247.
- a) N. J. Agard, J. A. Prescher and C. R. Bertozzi, *J. Am. Chem. Soc.* 2004, 126, 15046; b) J. M. Baskin, J. A. Prescher, S. T. Laughlin, N. J. Agard, P. V. Chang, I. A. Miller, A. Lo, J. A. Codelli and C. R. Bertozzi, *Proc. Natl. Acad. Sci. USA.* 2007, 104, 16793; c) E. M. Sletten and C. R. Bertozzi, *Acc. Chem. Res.* 2011, 44, 666.
- 8 a) T. Plass, S. Milles, C. Koehler, C. Schultz and E. A. Lemke, Angew. Chem. Int. Ed., 2011, 50, 3878; b) C. Schieber, A. Bestetti, J. P. Lim, A. D. Ryan, T. L. Nguyen, R. Eldridge, A. R. White, P. A. Gleeson, P. S. Donnelly, S. J. Williams and P. Mulvaney, Angew. Chem. Int. Ed. 2012, 51, 10523; c) P. Zhang, S. Liu, D. Gao, D. Hu, P. Gong, Z. Sheng, J. Deng, Y. Ma and L. Cai, J. Am. Chem. Soc. 2012, 134, 8388.
- a) K. Susumu, H. T. Uyeda, I. L. Medintz, T. Pons, J. B. Delehanty and H. Mattoussi, *J. Am. Chem. Soc.* 2007, **129**, 13987; b) B. C. Mei, K. Susumu, I. L. Medintz and H. Mattoussi, *Nat. Prot.* 2009, **4**, 412.
- a) K. L. Prime and G. M. Whitesides, *J. Am. Chem. Soc.* 1993, **115**,
  10774; b) D. Zhou, A. Bruckbauer, L. M. Ying, C. Abell and D. Klenerman, *Nano Lett.* 2003, **3**, 1517; c) D. J. Zhou, A. Bruckbauer, C. Abell, D. Klenerman and D. J. Kang, *Adv. Mater.* 2005, **17**, 1243.
- 11 a) Y. Kim, Z. Cao and W. Tan, *Proc. Natl. Acad. Sci. U.S.A.* 2008, **105**, 5664; b) C. J. Yang and W. Tan, *J. Am. Chem. Soc.* 2005, **127**, 12772; c) S. Tyagi, F. R. Kramer, *Nat. Biotechnol.* 1996, **14**, 303.
- a) R. McKendry, J. Zhang, Y. Arntz, T. Strunz, M. Hegner, H. P. Lang, M. K. Baller, U. Certa, E. Meyer, H.-J. Güntherodt and C. Gerber, *Proc. Natl. Acad. Sci. USA*. 2002, 99, 9783; b) J. Zhang, H. P. Lang, F. Huber, A. Bietsch, W. Grange, U. Certa, R. Mckendry, H.-J. Güntherodt, M. Hegner and C. Gerber, *Nature Nanotech.* 2006, 1, 214; c) C. Fan, K. W. Plaxco and A. J. Heeger, *Proc. Natl. Acad. Sci. U.S.A.* 2003, 100, 9134; d) A. A. Rowe, K. N. Chuh, A. A. Lubin, E. A. Miller, B. Cook, D. Hollis and K. W. Plaxco, *Anal. Chem.* 2011, 83, 9462; e) L. He, M. D. Musick, S. R. Nicewarner, F. G. Salinas, S.J. Benkovic, M. J. Natan and C. D. Keating, *J. Am. Chem. Soc.* 2000, 122, 9071; f) A. K., Deisingh and M. Thompson, *Analyst* 2001, 126, 2153; g) R. Polsky, R. Gill, L. Kaganovsky and I. Willner, *Anal. Chem.* 2006, 78, 2268.
- For a single QD FRET to n identical acceptors, the FRET efficiency, E, is given by:  $E = nR_0^6/[nR_0^6 + r^6] = 1/[1 + r^6/(nR_0^6)]$ , where  $R_0$  is the Förster radius and r is donor-acceptor distance. E can also be measured via the enhanced acceptor emission by the following equation:  $E = I_{Dye}/[I_{Dye} + I_{QD}] = 1/[1 + I_{QD}/I_{Dye}]$ . The combination of the two equations gives:  $1/[1 + I_{QD}/I_{Dye}] = 1/[1 + r^6/(nR_0^6)]$ , and therefore  $I_{Dye}/I_{QD} = n R_0^6/r^6$ , e.g.  $I_{Dye}/I_{QD}$  should increase linearly with n, the number of acceptors on each QD ([DNA29] here under a fixed [QD]) if all of the acceptors are hybridised to the QD with identical spatial configuration (identical r value).

- 14 a) A. W. Peterson, L. K. Wolf and R. M. Georgiadis, J. Am. Chem. Soc. 2002, 124, 14601; b) D. J. Zhou, K. Sinnah, C. Abell and T. Rayment, Angew. Chem. Int. Ed. 2003, 42, 4934.
- 15 a) M. K. Halushka, J. B. Fan, K. Bentley, L. Hsie, N. Shen, A. Weder, R. Cooper, R. Lipshutz and A. Chakravarti, Nat. Genet. 1999, 22, 239; b) Y. Zhang, Y. Guo, P. Quirke and D. J. Zhou, Nanoscale, 2013, 5, 5027.
- 16 a) D. H. J. Bunka and P. G. Stockley, Nat. Rev. Microbiol. 2006, 4, 588; b) J. Liu, Z. H. Cao and Y. Lu, Chem. Rev. 2009, 109, 1948.